Glaucoma Physician delivers timely information on the fast-evolving glaucoma space.
16/07/2025
Hear from inspiring women at the forefront of glaucoma care as they reflect on the mentors who guided them, the challenges they’ve overcome, and how the field continues to evolve for women in ophthalmology. Watch the roundtable discussion https://bit.ly/3UcxkoT and read the digital supplement: https://bit.ly/3GP1uLX
26/06/2025
Kevin J. Corcoran explains how saving time on chart notes, while keeping a detailed medical record, is valuable and can improve practice revenue. Read more: https://ow.ly/HOz150W6yXc
25/06/2025
Perfuse Therapeutics reports positive data from a phase 2 clinical trial of PER-001 for glaucoma. Read more: https://ow.ly/Joow50Wfx03
24/06/2025
Editor in Chief Nathan M. Radcliffe, MD, reflects on the skills needed for success in the era of interventional glaucoma. Read more: https://ow.ly/aEoX50W6z4W
23/06/2025
Arsham Sheybani, MD, and Tugce Turer discuss how targeting uveoscleral outflow may result in greater IOP reduction with fewer complications. Read more: https://ow.ly/vTQp50W6yxx
21/06/2025
A recent study finds that informing patients of a glaucoma diagnosis may impact their mental well-being. Read more: https://ow.ly/ULcB50W91sE
A European study found that IOP rises with increased physical intensity and drops after exercise, suggesting a dose-dependent effect. Read more: https://ow.ly/97pO50WaHfY
18/06/2025
Christine Funke, MD, and Deborah Ristvedt, DO, discuss how early therapeutic procedures can change the trajectory of glaucoma care. Read more: https://ow.ly/Rivp50W6yEM
Steven R. Sarkkisian Jr, MD, explains how a deliberate and proactive surgical strategy is necessary to achieve optimal outcomes. Read more: https://ow.ly/2Z5A50W6yvi
14/06/2025
Qlaris Bio is developing a fixed-dose combination therapy that combines its investigational drug QLS-111 with latanoprost. Read more: https://ow.ly/aNB150W7SP5
Be the first to know and let us send you an email when Glaucoma Physician posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
